Get the Stockscreener App
8.47
0.12%
-0.010
Pre-market:
8.56
0.09
+1.06%
Intellia Therapeutics Inc stock is traded at $8.47, with a volume of 5.58M.
It is down -0.12% in the last 24 hours and down -65.78% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$8.48
Open:
$8.45
24h Volume:
5.58M
Relative Volume:
0.72
Market Cap:
$982.24M
Revenue:
$52.86M
Net Income/Loss:
$-480.19M
P/E Ratio:
-1.806
EPS:
-4.6899
Net Cash Flow:
$-421.82M
1W Performance:
-16.80%
1M Performance:
-65.78%
6M Performance:
-0.35%
1Y Performance:
-40.23%
1-Day Range:
$8.22
$8.6298
1-Week Range:
$8.22
$10.33
52-Week Range:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
8.47 | 982.24M | 52.86M | -480.19M | -421.82M | -4.6899 |
|
ARGX
Argen X Se Adr
|
918.53 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.52 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.92 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.34 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-11-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Why Intellia Therapeutics Inc. (38I) stock remains top ratedTrade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
Will Intellia Therapeutics Inc. (38I) stock outperform value peers2025 Price Targets & Low Risk Entry Point Tips - newser.com
Will Intellia Therapeutics Inc. (38I) stock recover faster than industryJuly 2025 Fed Impact & Consistent Profit Trading Strategies - newser.com
Intellia Therapeutics Faces Weak Start with 10.21% Gap Down Amid Market Concerns - Markets Mojo
What data driven models say about Intellia Therapeutics Inc.’s futureFed Meeting & Daily Chart Pattern Signal Reports - newser.com
Intellia Therapeutics Stock (NTLA) Opinions on Clinical Trial Suspension - Quiver Quantitative
Can volume confirm reversal in Intellia Therapeutics Inc.Bull Run & Accurate Trade Setup Notifications - newser.com
Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data - Yahoo Finance
Can Intellia Therapeutics Inc. stock deliver surprise earnings beatWall Street Watch & Weekly Top Stock Performers List - newser.com
Will Intellia Therapeutics Inc. (38I) stock benefit from mergersPortfolio Profit Report & Verified Swing Trading Watchlists - newser.com
Intellia Therapeutics Shares Plunge on Clinical Trial Safety Concerns - AD HOC NEWS
Can technical indicators confirm Intellia Therapeutics Inc.’s reversal - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Is Intellia Therapeutics Inc. (38I) stock a buy on weaknessJuly 2025 Levels & Technical Entry and Exit Tips - newser.com
How Intellia Therapeutics Inc. stock reacts to oil prices2025 Market Trends & Fast Entry Momentum Trade Alerts - newser.com
Is Intellia Therapeutics Inc. stock a buy in volatile marketsMarket Trend Review & Free Reliable Trade Execution Plans - newser.com
How Intellia Therapeutics Inc. stock performs in weak economyJuly 2025 EndofMonth & Real-Time Volume Triggers - newser.com
2 Beaten-Down Stocks to Avoid Right Now - AOL.com
What to expect from Intellia Therapeutics Inc. in the next 30 days2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Is Intellia Therapeutics Inc. (38I) stock trading at attractive multiplesWeekly Risk Report & Community Consensus Trade Signals - newser.com
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? - Yahoo Finance
Intellia Therapeutics Reports Q3 2025 Financial Results - TipRanks
Can Intellia Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com
Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing - BioPharma Dive
Should You Buy the Dip in Intellia Therapeutics Stock? - Barchart.com
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.08%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):